SEARCH

SEARCH BY CITATION

References

  • 1
    Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747755.
  • 2
    Jordan SC, Tyan D. Intravenous gamma globulin (IVIG) inhibits lymphocytotoxic antibody in vitro. J Am Soc Nephrol 1991; 2: 803.
  • 3
    Yadin O, Sekiya NM, Ettenger RB. Intravenous immunoglobulin (IVIg) reduces antibody responses in highly sensitized dialysis patients. J Am Soc Nephrol 1992; 3: 887.
  • 4
    Glotz D, Haymann JP, Sansonetti N et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation 1993, 56: 335337.
  • 5
    Tyan D, Li V, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57: 553562 .
  • 6
    Glotz D, Haymann J, Naiudet P, Lang P, Druet P, Bairety J. Successful kidney transplantation of immunized patients after desensitization with normal human polyclonal immunoglobulins. Transpl Proc 1995; 27: 1038.
  • 7
    McIntyre JA, Higgins N, Britton R et al. Utilization of intravenous immunoglobulin to ameliorate alloantibodies in a highly sensitized patient with a cardiac assist device awaiting heart transplantation. Transplantation 1996; 62: 691693 .
  • 8
    De Marco T, Damon L, Colombe B et al. Successful immunomodulation with intravenous gamma globulin and cyclosphosphamide in an alloimmunized transplant patient. J Heart Lung Transplant 1997; 16: 360365.
  • 9
    Jordan SC, Adrianus WQ, Czer LSC et al. Posttransplant therapy using high-dose human IVIG to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanisms of action. Transplantation 1998; 66: 800805 .
  • 10
    Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887895.
  • 11
    Casadei DHC, Rial M, Opelz G et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001; 71: 5358.
  • 12
    Luke PP, Scantlebury VP, Jordan ML et al. Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 2001; 72: 419422.